At the front of its pipeline is ADCE-T02, a "highly differentiated" anti-tissue factor (TF) ADC that Adcendo licensed from Chinese biotech Multitude Therapeutics in the summer, in a deal with a ...

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms ...